UPMC Enterprises

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Percipio Health is a healthcare technology company that leverages artificial intelligence to enhance patient care. It provides a platform that integrates advanced computer vision software to monitor and assess patient health status. This technology enables clinicians and caregivers to maintain a comprehensive view of a patient's well-being and accurately identify medications. By offering AI-driven insights, Percipio Health empowers healthcare providers to make informed decisions, ultimately improving the quality of care delivered to patients.

Ouroboros Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic immune-mediated illnesses. It specializes in developing immune reset treatments, using a therapeutic platform that employs T cell engager antibodies to target and deplete specific pathogenic cells. This approach aims to provide extended remissions for patients, without the need for ongoing immunosuppression. The company's strength lies in its integration of scientific knowledge and proven track record in progressing cell-depleting treatments through clinical trials, supported by a robust pipeline.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Pip Care is a healthcare company offering a personalized surgical journey platform that digitizes and automates perioperative processes for health systems. The platform supports care teams from preparation to recovery, with a perioperative care app to help patients prepare for and recover from surgery. The company also provides certified health coaches who develop personalized recovery plans with daily tasks and curated advice, enabling patients to track appointments and stay prepared. By aligning care teams and patient steps, Pip Care aims to improve surgical outcomes and efficiency for health systems.

Medicom Technologies, Inc. is a technology company based in Raleigh, North Carolina, that specializes in improving patient care through innovative health information solutions. The company addresses interoperability challenges in healthcare by providing a network that consolidates a patient's complete medical history into an easily navigable interface. This network eliminates the need for traditional methods of sharing clinical information, such as faxes and CD-ROMs, by connecting over 2,000 healthcare organizations through more than 3,500 unique connections. Medicom offers several key products, including Imagex, a diagnostic image transfer solution; Endpoint, an image archiving system; and Hex, a patient record exchange network. Additionally, the company features the deepMed Marketplace, which supports healthcare data consumers in life sciences and pharmaceuticals by facilitating the curation of extensive longitudinal data sets for research and AI applications. Founded by Michael Rosenberg, Malcolm Benitz, and Chase Ballard, Medicom is dedicated to transforming how healthcare information is shared and utilized.

BrainCheck, Inc. is a Houston-based company that specializes in cognitive health solutions for healthcare and athletic organizations across the United States. Established in 2013, BrainCheck offers a comprehensive application designed to assist individuals in making informed decisions regarding their cognitive health. This application includes a screening tool and interactive tests that can be accessed on mobile devices or browsers, allowing users to evaluate their brain health and receive immediate results. The platform facilitates connections between patients and care teams, particularly in the concussion and dementia markets, enabling clinicians to monitor significant changes in cognitive health and share results efficiently.

Helexva operates as a biotech company that specializes in treatment for fatal neurodegenerative diseases.

Elektra Health is a digital health platform focused on perimenopause and menopause. It addresses gaps in care by offering education, community, and access to medical expertise, helping women navigate hormonal changes with reduced stigma. The service provides telemedicine with clinicians, an evidence-based educational program, and a private community to support informed decision-making and ongoing management of menopause symptoms. By combining information, clinical care, and peer support, Elektra Health aims to empower women to maintain wellbeing as they transition through perimenopause and menopause.

Sudo Biosciences is a biopharmaceutical company focused on developing innovative medicines targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, which plays a critical role in immune-mediated inflammatory conditions. Its pipeline includes next-generation TYK2 inhibitors for treating multiple sclerosis and other neuroinflammatory diseases, as well as topical candidates for immune-mediated dermatologic conditions.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Founded in 2015, Siempre Health operates a platform that dynamically adjusts patient co-payments based on medication adherence. It works with health plans and pharmaceutical manufacturers to improve clinical outcomes by incentivizing patients to fill prescriptions promptly via SMS reminders and discounts.

GenSight Biologics is a clinical-stage biotechnology company focused on developing therapies for mitochondrial and neurodegenerative diseases of the eye. It uses gene therapy-based platforms, Mitochondrial Targeting Sequence and Optogenetics, to preserve or restore vision in patients with severe degenerative retinal diseases.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Clearsense, LLC is a healthcare technology company based in Jacksonville, Florida, founded in 2013. The company specializes in providing a cloud-based data platform that offers healthcare analytics and data management solutions for organizations and patients. Its platform, known as the Clearsense Data Management Platform, aggregates and manages data from various sources, facilitating real-time insights into clinical, operational, and financial metrics. By converting disparate data into a single source of truth, Clearsense enhances data maturity and optimizes analytics tools, ultimately improving decision-making and driving meaningful outcomes. The platform is designed to be secure and scalable, empowering healthcare organizations to leverage their data effectively, reduce costs, and seize new revenue opportunities.

Smile Digital Health is a health information technology company that focuses on providing data fabric solutions tailored for the healthcare sector. The company develops fast, secure, and compliant data infrastructures designed to support the complex data needs of healthcare organizations. Its enterprise-grade, open-framework platform facilitates the digital transformation of healthcare by enabling seamless collaboration and integration across various systems. This allows organizations to effectively ingest, transform, store, analyze, and share health information, ultimately enhancing patient care and driving value creation throughout the healthcare ecosystem.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Founded in 2018, Redesign Health is a global venture builder empowering founders to launch and scale transformative healthcare companies. Since its inception, it has supported over two dozen companies impacting more than ten million lives across various healthcare sectors.

Abridge is a healthcare technology company that uses generative AI to automate transcription and summarization of medical conversations. The platform turns patient-clinician discussions into structured clinical notes in real time and integrates with electronic health record systems. By reducing manual note-taking, it helps clinicians capture key details while producing clear summaries for patients, and ensures documentation is added to patient records. Abridge emphasizes data security and patient privacy, complies with healthcare regulations, and provides a customizable interface aligned with clinical workflows and patient needs.

Novasenta is a pharmaceutical company focused on developing innovative immunotherapy treatments for cancer. Founded in 2018 and headquartered in Pittsburgh, Pennsylvania, the company employs a systematic and rigorous approach to analyze human tumor microenvironments, aiming to uncover new druggable targets. By utilizing single-cell level analysis of high-quality human tumor samples and advanced data mining techniques, Novasenta accelerates the transition from discovery to patient-ready therapies. The company specializes in immuno-oncology therapeutics, leveraging a machine-learning-enabled platform to identify immune networks and potential drug targets within the tumor microenvironment. Through its research efforts, Novasenta seeks to provide patients with safer and more effective cancer treatments.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Moxe Health specializes in facilitating the exchange of clinical data between health plans and provider systems. Its platform, Substrate, enables real-time, bi-directional data transfer, including clinical, analytic, and administrative information. Moxe's solutions cover risk adjustment, quality metrics (like HEDIS and Star ratings), claims management, and care gap management, ensuring health plans and providers have the necessary data for value-based care. The company's neutrality allows seamless integration with existing systems, maximizing investments in population health and analytics.

Hashed Health is a collaborative healthcare innovation firm that builds an ecosystem of businesses using blockchain infrastructure to address healthcare challenges. It focuses on asset exchanges, multi-party business process automation, and data custody initiatives, partnering with enterprises to solve complex problems collectively.

BrainCheck, Inc. is a Houston-based company that specializes in cognitive health solutions for healthcare and athletic organizations across the United States. Established in 2013, BrainCheck offers a comprehensive application designed to assist individuals in making informed decisions regarding their cognitive health. This application includes a screening tool and interactive tests that can be accessed on mobile devices or browsers, allowing users to evaluate their brain health and receive immediate results. The platform facilitates connections between patients and care teams, particularly in the concussion and dementia markets, enabling clinicians to monitor significant changes in cognitive health and share results efficiently.

Smile Digital Health is a health information technology company that focuses on providing data fabric solutions tailored for the healthcare sector. The company develops fast, secure, and compliant data infrastructures designed to support the complex data needs of healthcare organizations. Its enterprise-grade, open-framework platform facilitates the digital transformation of healthcare by enabling seamless collaboration and integration across various systems. This allows organizations to effectively ingest, transform, store, analyze, and share health information, ultimately enhancing patient care and driving value creation throughout the healthcare ecosystem.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Founded in 2015, Siempre Health operates a platform that dynamically adjusts patient co-payments based on medication adherence. It works with health plans and pharmaceutical manufacturers to improve clinical outcomes by incentivizing patients to fill prescriptions promptly via SMS reminders and discounts.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Butterfly Network is a medical technology company developing handheld ultrasound systems that aim to democratize imaging and expand access to care. Its flagship device, a single-probe handheld system powered by Ultrasound-on-Chip semiconductor technology, enables whole-body diagnostic imaging with cloud-connected software and a mobile application, allowing clinicians to acquire, store, and analyze ultrasound data in real time. The platform supports workflow integration for hospitals and outpatient settings, and can image vascular, cardiac, abdominal, urological, fetal, gynecological, and musculoskeletal regions. The company envisions improving early detection and remote management of health conditions by enabling pocket-sized imaging capability and scalable ultrasound programs across healthcare facilities. Butterfly Network was founded with a mission to advance global health equity by increasing ultrasound access worldwide. The technology combines a compact hardware device with software to streamline acquisition, interpretation, and sharing of ultrasound information in clinical workflows.

Moxe Health specializes in facilitating the exchange of clinical data between health plans and provider systems. Its platform, Substrate, enables real-time, bi-directional data transfer, including clinical, analytic, and administrative information. Moxe's solutions cover risk adjustment, quality metrics (like HEDIS and Star ratings), claims management, and care gap management, ensuring health plans and providers have the necessary data for value-based care. The company's neutrality allows seamless integration with existing systems, maximizing investments in population health and analytics.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Founded in 2017, the company is dedicated to creating therapeutics that stimulate the body’s immune system to combat cancer. Utilizing its proprietary PREDATOR platform, Werewolf designs conditionally activated molecules known as INDUKINE, which are engineered to remain inactive in peripheral tissues while selectively activating within the tumor microenvironment. This approach aims to overcome the limitations of traditional proinflammatory immune therapies, enhancing both adaptive and innate immunity to improve cancer treatment outcomes.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Cerevance develops novel therapeutics for neurological disorders such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. It uses a proprietary platform to profile specific brain cell types in human tissue samples, enabling the identification of promising targets for new treatments.

Carta Healthcare provides a software-as-a-service platform that maps the patient journey through hospitals by integrating data from existing information systems. The platform identifies potential bottlenecks weeks in advance and issues alerts about bed shortages and cancellations. It enables hospitals to personalize care by analyzing past patient journeys and using machine learning to predict what the current patient will need and what to expect during treatment. Its clinical data abstraction capabilities automate extraction and processing to improve efficiency, accuracy, and compliance. The solution supports hospitals and research organizations in optimizing patient care, resource allocation, and operational decisions. Founded in 2016 and based in San Mateo, California, Carta Healthcare focuses on turning disparate clinical data into actionable insights to improve care delivery.